Posted by Michael Wonder on 17 May 2019
Celgene receives European Commission approvals for Revlimid (lenalidomide) and Imnovid (pomalidomide)-based triplet combination regimens for patients with multiple myeloma
16 May 2019 - The European Commission has approved two of Celgene’s IMiD based combination regimens.
Celgene Corporation today announced that the European Commission has approved two new triplet regimens based on Celgene’s proprietary IMiD treatments, Revlimid (lenalidomide) and Imnovid (pomalidomide).
Revlimid in combination with bortezomib and dexamethasone, is now indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. In addition, Imnovid, in combination with bortezomib and dexamethasone, is now indicated for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.
